Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine

被引:11
作者
Deininger, Kimberly M. [1 ]
Page, Robert L., II [2 ]
Lee, Yee Ming [2 ]
Kauffman, Yardlee S. [3 ]
Johnson, Samuel G. [4 ,5 ]
Oreschak, Kris [1 ]
Aquilante, Christina L. [1 ]
机构
[1] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[2] Univ Colorado, Dept Clin Pharm, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA
[3] Univ Sci, Dept Pharm Practice & Pharm Adm, Philadelphia, PA USA
[4] Board Pharm Specialties, Washington, DC USA
[5] Virginia Commonwealth Univ, Sch Pharm, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA USA
关键词
cardiologist; cardiology; clinical implementation; personalized medicine; pharmacogenetic; pharmacogenomic; qualitative research; IMPLEMENTATION CONSORTIUM GUIDELINES; CLINICAL UTILITY; CYP2C19; GENOTYPE; CPIC GUIDELINES; PROFESSIONALS; PHARMACISTS; PERCEPTIONS; ATTITUDES; THERAPY; VIEWS;
D O I
10.2217/pme-2018-0099
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To evaluate factors influencing cardiologists' perspectives about pharmacogenomic (PGx) testing in clinical practice. Patients & methods: Semistructured interviews with practicing cardiologists were qualitatively analyzed to identify common themes. Results: Five themes were identified among 16 cardiologists from four specialties (n=5 general cardiology, n=3 electrophysiology, n=2 adult congenital and n=6 heart failure/transplant): cardiologists' knowledge and needs, perceived clinical validity and utility of PGx testing, dissemination and management of PGx results, patient-related considerations and incidental findings. Conclusion: Lack of evidence was considered by many cardiologists to be a major barrier hindering the use of PGx testing. However, they would consider adopting PGx if they were provided additional education, ongoing support and evidence supporting the clinical utility of PGx testing in cardiovascular medicine.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 32 条
[1]   Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing [J].
Birdwell, K. A. ;
Decker, B. ;
Barbarino, J. M. ;
Peterson, J. F. ;
Stein, C. M. ;
Sadee, W. ;
Wang, D. ;
Vinks, A. A. ;
He, Y. ;
Swen, J. J. ;
Leeder, J. S. ;
van Schaik, R. H. N. ;
Thummel, K. E. ;
Klein, T. E. ;
Caudle, K. E. ;
MacPhee, I. A. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) :19-24
[2]  
Carroll JC, 2016, CAN FAM PHYSICIAN, V62, pE626
[3]   Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process [J].
Caudle, Kelly E. ;
Klein, Teri E. ;
Hoffman, James M. ;
Mueller, Daniel J. ;
Whirl-Carrillo, Michelle ;
Gong, Li ;
McDonagh, Ellen M. ;
Sangkuhl, Katrin ;
Thorn, Caroline F. ;
Schwab, Matthias ;
Agundez, Jose A. G. ;
Freimuth, Robert R. ;
Huser, Vojtech ;
Lee, Ming Ta Michael ;
Iwuchukwu, Otito F. ;
Crews, Kristine R. ;
Scott, Stuart A. ;
Wadelius, Mia ;
Swen, Jesse J. ;
Tyndale, Rachel F. ;
Stein, C. Michael ;
Roden, Dan ;
Relling, Mary V. ;
Williams, Marc S. ;
Johnson, Samuel G. .
CURRENT DRUG METABOLISM, 2014, 15 (02) :209-217
[4]   Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention [J].
Cavallari, Larisa H. ;
Lee, Craig R. ;
Beitelshees, Amber L. ;
Cooper-DeHoff, Rhonda M. ;
Duarte, Julio D. ;
Voora, Deepak ;
Kimmel, Stephen E. ;
McDonough, Caitrin W. ;
Gong, Yan ;
Dave, Chintan V. ;
Pratt, Victoria M. ;
Alestock, Tameka D. ;
Anderson, R. David ;
Alsip, Jorge ;
Ardati, Amer K. ;
Brott, Brigitta C. ;
Brown, Lawrence ;
Chumnumwat, Supatat ;
Clare-Salzler, Michael J. ;
Coons, James C. ;
Denny, Joshua C. ;
Dillon, Chrisly ;
Elsey, Amanda R. ;
Hamadeh, Issam S. ;
Harada, Shuko ;
Hillegass, William B. ;
Hines, Lindsay ;
Horenstein, Richard B. ;
Howell, Lucius A. ;
Jeng, Linda J. B. ;
Kelemen, Mark D. ;
Lee, Yee Ming ;
Magvanjav, Oyunbileg ;
Montasser, May ;
Nelson, David R. ;
Nutescu, Edith A. ;
Nwaba, Devon C. ;
Pakyz, Ruth E. ;
Palmer, Kathleen ;
Peterson, Josh F. ;
Pollin, Toni I. ;
Quinn, Alison H. ;
Robinson, Shawn W. ;
Schub, Jamie ;
Skaar, Todd C. ;
Smith, D. Max ;
Sriramoju, Vindhya B. ;
Starostik, Petr ;
Stys, Tomasz P. ;
Stevenson, James M. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (02) :181-191
[5]   Exploration of the perceptions, barriers and drivers of pharmacogenomics practice among hospital pharmacists in Adelaide, South Australia [J].
Dias, M. M. ;
Ward, H. M. ;
Sorich, M. J. ;
McKinnon, R. A. .
PHARMACOGENOMICS JOURNAL, 2014, 14 (03) :235-240
[6]   Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers [J].
Dunnenberger, Henry M. ;
Crews, Kristine R. ;
Hoffman, James M. ;
Caudle, Kelly E. ;
Broeckel, Ulrich ;
Howard, Scott C. ;
Hunkler, Robert J. ;
Klein, Teri E. ;
Evans, William E. ;
Relling, Mary V. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55, 2015, 55 :89-+
[7]   Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS [J].
Fargher, Emily A. ;
Eddy, Charlotte ;
Newman, William ;
Qasim, Faieza ;
Tricker, Karen ;
Elliott, Rachel A. ;
Payne, Katherine .
PHARMACOGENOMICS, 2007, 8 (11) :1511-1519
[8]  
Fereday J., 2006, INT J QUAL METH, V5, P80, DOI 10.1177/160940690600500107
[9]   Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues [J].
Gillis, N. K. ;
Innocenti, F. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (06) :655-657
[10]   ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing [J].
Green, Robert C. ;
Berg, Jonathan S. ;
Grody, Wayne W. ;
Kalia, Sarah S. ;
Korf, Bruce R. ;
Martin, Christa L. ;
McGuire, Amy L. ;
Nussbaum, Robert L. ;
O'Daniel, Julianne M. ;
Ormond, Kelly E. ;
Rehm, Heidi L. ;
Watson, Michael S. ;
Williams, Marc S. ;
Biesecker, Leslie G. .
GENETICS IN MEDICINE, 2013, 15 (07) :565-574